

STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 201204

TO: Ben Sackey
Location: 5b31 / 5c18
Art Unit: 1626
Monday, September 18, 2006

Case Serial Number: 10/702149

From: Noble Jarrell
Location: Biotech-Chem Library
Rem 1B71
Phone: 272-2556

Noble.jarrell@uspto.gov

Search Notes

FOR OFFICIAL USE ONLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: BEN SACKY Examiner #: 73489 Date: 9/10/06
Art Unit: 1622 Phone Number: 2-0704 Serial Number: 12/702,105
Location (Bldg/Room#): _____ (Mailbox #): _____ Results Format Preferred (circle): PAPER DISK

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: Compound 10.1


Inventors (please provide full names): _____

Earliest Priority Date: _____

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.



STAFF USE ONLY

Searcher: Wife

Searcher Phone #: _____

Searcher Location: _____

Date Searcher Picked Up: 9/18/06

Date Completed: 9/18/06

Searcher Prep & Review Time: 15

Online Time: 37

Type of Search

____ NA Sequence (#)

____ AA Sequence (#)

1 Structure (#)

2 Bibliographic

____ Litigation

____ Fulltext

____ Other

Vendors and cost where applicable

____ STN _____ Dialog

____ Questel/Orbit _____ Lexis/Nexis

____ Westlaw _____ WWW/Internet

____ In-house sequence systems

____ Commercial _____ Oligomer _____ Score/Length

____ Interference _____ SPDI _____ Encode/Transl

____ Other (specify)

=> b reg

FILE 'REGISTRY' ENTERED AT 14:35:41 ON 18 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 SEP 2006 HIGHEST RN 907180-17-0

DICTIONARY FILE UPDATES: 17 SEP 2006 HIGHEST RN 907180-17-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Effective September 24, 2006, Concord 3D coordinates will no longer be available. Please contact CAS Customer Care (<http://www.cas.org/supp.html>) if you have a need for 3D coordinates.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d que sta l16

L10 STR



Ak-C-G5
26 @27 28

O-Ak
@29 30

G3-G4-C-G6
19 20 21 31

NH-G7
@33 34

G7-N-G7
35 @36 37

Ak-Cy
@44 45

46
O
|||
C-G1-G8
@38 39 40

47
O
|||
@41 S-G1-G8
||| 42 43
D
48

REP G1=(0-2) C

VAR G2=H/AK/X/CN

VAR G3=1/6

VAR G4=22/24/27

VAR G5=OH/29

VAR G6=NH2/32/33/36

VAR G7=AK/CY/38/41/44

VAR G8=AK/CY

NODE ATTRIBUTES:

NSPEC IS R AT 32

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 48

STEREO ATTRIBUTES: NONE

L12 1309520 SEA FILE=REGISTRY ABB=ON PLU=ON (NCNC2 OR N2C3)/ES
L14 SCR 1994 AND 1839
L16 347 SEA FILE=REGISTRY SUB=L12 SSS FUL L10 AND L14

100.0% PROCESSED 939920 ITERATIONS 347 ANSWERS
SEARCH TIME: 00.00.33

=> b hcap;d bib abs fhitrn hitrn retable l19 tot
FILE 'HCAPLUS' ENTERED AT 14:36:20 ON 18 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Sep 2006 VOL 145 ISS 13
FILE LAST UPDATED: 17 Sep 2006 (20060917/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

L19 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:160837 HCAPLUS

DN 142:233372

TI Pharmaceutical composition using a combination of an opioid receptor antagonist and a CB-1 receptor antagonist for the prevention and treatment of addiction in a mammal

IN Coe, Jotham Wadsworth; Iredale, Philip A.; McHardy, Stanton Furst; McLean, Stafford

PA Pfizer Inc, USA

SO U.S. Pat. Appl. Publ., 25 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US2005043327	A1	20050224	2004US-0870209	20040617
	CA--2536280	AA	20050303	2004CA-2536280	20040809
	WO2005018645	A1	20050303	2004WO-IB02596	20040809
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

EP---1658082 A1 20060524 2004EP-0744231 20040809

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

PRAI 2003US-496803P P 20030821

2004WO-IB02596 W 20040809

AB Pharmaceutical compns. are disclosed for the treatment of alc. or cocaine dependence or addiction, tobacco dependence or addiction, reduction of alc. withdrawal symptoms or aiding in the cessation or lessening of alc. use or substance abuse or other behavioral dependencies including gambling. The pharmaceutical compns. are comprised of a therapeutically effective combination of an opioid receptor antagonist and a CB-1 receptor antagonist and a pharmaceutically acceptable carrier. The method of using these compds. is also disclosed.


IT 709033-15-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(opioid receptor antagonist-CB-1 receptor antagonist combination for prevention and treatment of addiction)

RN 709033-15-8 HCAPLUS

CN Ethanone, 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-2-(1-piperidiny)- (9CI) (CA INDEX NAME)



IT 709033-15-8 709033-17-0 709033-18-1

709033-19-2 709033-20-5 709033-21-6

709033-22-7 709033-23-8 709033-25-0

709033-27-2 709033-29-4 709033-30-7

709033-31-8 709033-32-9 709033-33-0

709033-34-1 709033-35-2 709033-41-0

709033-42-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(opioid receptor antagonist-CB-1 receptor antagonist combination for prevention and treatment of addiction)

L19 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:515489 HCAPLUS

DN 141:54345

TI Preparation of pyrazoles and imidazoles as cannabinoid CB1 receptor antagonists.

IN Dow, Robert Lee; Hammond, Marlys

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 102 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004052864	A1	20040624	2003WO-IB05835	20031203 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US2004122074	A1	20040624	2003US-0702149	20031104 <--
	CA--2505887	AA	20040624	2003CA-2505887	20031203 <--
	AU2003286315	A1	20040630	2003AU-0286315	20031203 <--
	EP--1572662	A1	20050914	2003EP-0777058	20031203 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR2003017096	A	20051025	2003BR-0017096	20031203 <--
	JP2006514942	T2	20060518	2004JP-0558286	20031203 <--
PRAI	2002US-432911P	P	20021212	<--	
	2003WO-IB05835	W	20031203		
OS	MARPAT 141:54345				
GI					




I

AB Title compds. [I; X = C and Y = N, or X = N and Y = C; R1 = H, alkyl, halo, cyano; R2, R3 = (CH2)nAr; m, n = 0-2; p = 0-3; Ar = (substituted) aryl, heteroaryl; L = CO, CR4OR5; R4 = H, alkyl; R5 = H, alkyl; R5R8, R5R9 = CH2CH2, CH2CO; R6, R7 = H, alkyl; R6R7 = atoms to form a (partially) saturated carbocyclic ring; R8, R9 = H, alkyl, CO(CH2)mR10, SO2(CH2)nR10, (CH2)pR10; R8R9 = atoms to form a 4-8 membered (partially) saturated ring; R10 = (substituted) alkyl, (partially) saturated cycloalkyl, aryl, heteroaryl, heterocyclyl; dotted lines = bonds for form an aromatic ring], were prepared for treatment of obesity, alcoholism, or tobacco abuse (no data). Thus, 2-(benzylisopropylamino)-1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]ethanone hydrochloride was stirred with NaBH4 in EtOH to give 2-(benzylisopropylamino)-1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]ethanol.

IT 709033-15-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (claimed compound; preparation of pyrazoles and imidazoles as cannabinoid CB1 receptor antagonists)

RN 709033-15-8 HCAPLUS

CN Ethanone, 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)



IT 709033-15-8P 709033-17-0P 709033-18-1P
 709033-19-2P 709033-20-5P 709033-21-6P
 709033-22-7P 709033-23-8P 709033-25-0P
 709033-27-2P 709033-29-4P 709033-30-7P
 709033-31-8P 709033-32-9P 709033-33-0P
 709033-34-1P 709033-35-2P 709033-41-0P
 709033-42-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(claimed compound; preparation of pyrazoles and imidazoles as cannabinoid CB1
 receptor antagonists)

IT 709033-46-5P 709033-47-6P 709033-48-7P
 709033-50-1P 709033-52-3P 709033-54-5P
 709033-56-7P 709033-58-9P 709033-60-3P
 709033-62-5P 709033-63-6P 709033-66-9P
 709033-70-5P 709033-74-9P 709033-76-1P
 709033-78-3P 709033-80-7P 709033-82-9P
 709033-84-1P 709033-86-3P 709033-88-5P
 709033-89-6P 709033-90-9P 709033-91-0P
 709033-92-1P 709033-93-2P 709033-94-3P
 709033-95-4P 709033-96-5P 709033-97-6P
 709033-98-7P 709033-99-8P 709034-00-4P
 709034-01-5P 709034-02-6P 709034-03-7P
 709034-04-8P 709034-05-9P 709034-06-0P
 709034-07-1P 709034-08-2P 709034-09-3P
 709034-10-6P 709034-11-7P 709034-12-8P
 709034-13-9P 709034-14-0P 709034-15-1P
 709034-16-2P 709034-17-3P 709034-18-4P
 709034-19-5P 709034-20-8P 709034-21-9P
 709034-22-0P 709034-23-1P 709034-24-2P
 709034-25-3P 709034-26-4P 709034-27-5P
 709034-28-6P 709034-29-7P 709034-30-0P
 709034-31-1P 709034-32-2P 709034-33-3P
 709034-34-4P 709034-35-5P 709034-36-6P
 709034-37-7P 709034-38-8P 709034-39-9P
 709034-40-2P 709034-41-3P 709034-42-4P
 709034-44-6P 709034-45-7P 709034-46-8P
 709034-47-9P 709034-48-0P 709034-49-1P
 709034-50-4P 709034-51-5P 709034-52-6P
 709034-53-7P 709034-54-8P 709034-55-9P
 709034-56-0P 709034-57-1P 709034-58-2P
 709034-59-3P 709034-60-6P 709034-61-7P
 709034-62-8P 709034-63-9P 709034-64-0P
 709034-65-1P 709034-66-2P 709034-67-3P
 709034-68-4P 709034-69-5P 709034-70-8P
 709034-71-9P 709034-72-0P 709034-73-1P
 709034-74-2P 709034-75-3P 709034-76-4P
 709034-77-5P 709034-78-6P 709034-79-7P
 709034-80-0P 709034-81-1P 709034-82-2P
 709034-83-3P 709034-84-4P 709034-85-5P
 709034-86-6P 709034-87-7P 709034-88-8P

709034-89-9P 709034-90-2P 709034-91-3P
709034-92-4P 709034-93-5P 709034-94-6P
709034-95-7P 709034-96-8P 709034-97-9P
709034-98-0P 709034-99-1P 709035-00-7P
709035-01-8P 709035-02-9P 709035-03-0P
709035-04-1P 709035-05-2P 709035-06-3P
709035-07-4P 709035-08-5P 709035-09-6P
709035-10-9P 709035-11-0P 709035-12-1P
709035-13-2P 709035-14-3P 709035-15-4P
709035-16-5P 709035-17-6P 709035-18-7P
709035-19-8P 709035-20-1P 709035-21-2P
709035-22-3P 709035-23-4P 709035-24-5P
709035-25-6P 709035-26-7P 709035-27-8P
709035-28-9P 709035-29-0P 709035-30-3P
709035-31-4P 709035-32-5P 709035-33-6P
709035-34-7P 709035-35-8P 709035-36-9P
709035-37-0P 709035-38-1P 709035-39-2P
709035-40-5P 709035-41-6P 709035-42-7P
709035-43-8P 709035-44-9P 709035-45-0P
709035-46-1P 709035-47-2P 709035-48-3P
709035-49-4P 709035-50-7P 709035-51-8P
709035-52-9P 709035-53-0P 709035-54-1P
709035-55-2P 709035-56-3P 709035-57-4P
709035-58-5P 709035-59-6P 709035-60-9P
709035-61-0P 709035-62-1P 709035-63-2P
709035-64-3P 709035-65-4P 709035-66-5P
709035-67-6P 709035-68-7P 709035-69-8P
709035-70-1P 709035-71-2P 709035-72-3P
709035-73-4P 709035-74-5P 709035-75-6P
709035-76-7P 709035-77-8P 709035-78-9P
709035-79-0P 709035-80-3P 709035-81-4P
709035-82-5P 709035-83-6P 709035-84-7P
709035-85-8P 709035-86-9P 709035-87-0P
709035-88-1P 709035-89-2P 709035-90-5P
709035-92-7P 709035-94-9P 709035-95-0P
709035-96-1P 709035-97-2P 709035-98-3P
709035-99-4P 709036-00-0P 709036-01-1P
709036-02-2P 709036-03-3P 709036-04-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of pyrazoles and imidazoles as cannabinoid CB1 receptor
antagonists)

IT 709036-05-5P 709036-06-6P 709036-07-7P
709036-08-8P 709036-10-2P 709036-12-4P
709036-15-7P 709036-18-0P 709036-21-5P
709036-24-8P 709036-26-0P 709036-28-2P
709036-31-7P 709036-33-9P 709036-35-1P
709036-37-3P 709036-38-4P 709036-39-5P
709036-40-8P 709036-41-9P 709036-42-0P
709036-43-1P 709036-44-2P 709036-45-3P
709036-46-4P 709036-47-5P 709036-48-6P
709036-49-7P 709036-50-0P 709036-51-1P
709036-52-2P 709036-53-3P 709036-54-4P
709036-68-0P 709036-69-1P 709036-70-4P
709036-71-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of pyrazoles and imidazoles as cannabinoid CB1 receptor
antagonists)

IT 709036-72-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrazoles and imidazoles as cannabinoid CB1 receptor
antagonists)

=> d bib abs hitstr retable 120 tot

L20 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1989:135273 HCAPLUS

DN 110:135273

TI Preparation of substituted imidazolylalkylpiperazines and -diazepines as pharmaceuticals

IN Pascal, Jean Claude; Lee, Chi Ho; Alps, Brian J.; Pinhas, Henri; Whiting, Roger L.; Beranger, Serge

PA Syntex Pharmaceuticals Ltd., UK

SO Eur. Pat. Appl., 44 pp.


CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP---289227	A1	19881102	1988EP-0303646	19880422
	EP---289227	B1	19920408		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US---4829065	A	19890509	1987US-0042181	19870424
	DK---8802204	A	19881025	1988DK-0002204	19880422
	FI---8801900	A	19881025	1988FI-0001900	19880422
	FI-----93104	B	19941115		
	FI-----93104	C	19950227		
	NO---8801789	A	19881025	1988NO-0001789	19880422
	NO---170018	B	19920525		
	NO---170018	C	19920902		
	AU---8815102	A1	19881027	1988AU-0015102	19880422
	AU---614282	B2	19910829		
	JP---63280081	A2	19881117	1988JP-0101194	19880422
	JP--07037451	B4	19950426		
	HU-----46690	A2	19881128	1988HU-0002048	19880422
	HU---199456	B	19900228		
	ZA---8802878	A	19891227	1988ZA-0002878	19880422
	AT-----74594	E	19920415	1988AT-0303646	19880422
	IL-----86149	A1	19930114	1988IL-0086149	19880422
	CA---1320199	A1	19930713	1988CA-0564939	19880422
	ES---2038288	T3	19930716	1988ES-0303646	19880422
	US---5043447	A	19910827	1988US-0260969	19881021
	US---5142052	A	19920825	1988US-0260965	19881021
	US---4935417	A	19900619	1989US-0313656	19890221
	US---5010075	A	19910423	1990US-0505379	19900406
	US---5091428	A	19920225	1991US-0652141	19910207
	US---5276034	A	19940104	1991US-0688193	19910419
	US---5252736	A	19931012	1991US-0789230	19911107
	US---5514800	A	19960507	1993US-0124518	19930920
PRAI	1987US-0042181	A	19870424		
	1988EP-0303646	A	19880422		
	1988US-0260969	A3	19881021		
	1989US-0313656	A3	19890221		
	1990US-0505379	A3	19900406		
	1991US-0652141	A1	19910207		
	1991US-0688193	A3	19910419		
OS	MARPAT 110:135273				
GI					




AB Title compds. I (R1,R4,R5 = aryl; R2 = aryl, alkyl, H; R3 = alkyl, OH, H; m = 2, 3; n = 0-2, or n = 0, 2 when R3 = OH; q = 0-3) useful as Ca entry blockers (no data) are prepared To a refluxing solution of N-(diphenylmethyl)piperazine and NaOH in EtOH-H2O (3:2) was added a solution of 2-(4-methylphenyl)-4-chloromethyl-5-methyl-1H-imidazole.HCl (preparation given) in EtOH-H2O (3:2) to give 70% I (R1 = p-MeC6H4; R2 = Me; R3 = H; R4 = R5 = Ph; m = 2; n = q = 0) (II). II.3HCl at 5 mg/kg p.o. showed .apprx.5.7, .apprx.9.5, and .apprx.11.8 mL urine collected after 1, 3, and 6 h, resp. of administration in normotensive rats, vs. .apprx.3.3, .apprx.7.3, and .apprx.5.6 mL for control, resp. and no significant kaliuretic effects were observed A tablet was formulated containing I 25, cornstarch 20, lactose 153, and Mg stearate 2 mg.

IT 119514-74-8P 119514-82-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as pharmaceutical)


RN 119514-74-8 HCAPLUS

CN Ethanone, 2-[4-(diphenylmethyl)-1-piperazinyl]-1-(5-methyl-2-phenyl-1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)



RN 119514-82-8 HCAPLUS

CN 1-Piperazineethanol, 4-(diphenylmethyl)-α-(5-methyl-2-phenyl-1H-imidazol-4-yl)-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

L20 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1988:454791 HCAPLUS

DN 109:54791

TI Preparation of 1-[(5-methyl-2-(pyridyl)-1H-imidazol-4-yl]-2-[(4-substituted)-1-piperazinyl]ethanols as antihypertensives

IN Hofmann, Corris M.; Newman, Howard; Tomcufcik, Andrew S.

PA American Cyanamid Co., USA

SO U.S., 8 pp.


CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US---4732895	A	19880322	1986US-0858633	19860502
PRAI	1986US-0858633		19860502		
OS	CASREACT 109:54791; MARPAT 109:54791				
GI					



AB The title compds. [I; R1 = (substituted) Ph, heterocyclyl; R2 = H, alkyl; R3 = H, Ph, alkyl], useful as antihypertensives, are prepared I [R1 = Ph, R2 = 5-Me (3-pyridyl), R3 = H] (II) was prepared via NaBH₄ reduction of the corresponding ethanone derivative, which was obtained via condensation of 2-bromo-1-[5-methyl-2-(5-methyl-3-pyridyl)-1H-imidazol-4-yl]-1-ethanone with 1-phenylpiperazine. II at 25 mg/kg orally reduced mean arterial blood pressure in spontaneously hypertensive rats from 160 mmHg to 88 mmHg.


IT 115328-37-5P 115328-38-6P 115328-39-7P
 115328-40-0P 115328-41-1P 115328-42-2P
 115328-43-3P 115328-44-4P 115328-45-5P
 115328-46-6P 115328-47-7P 115328-48-8P
 115328-49-9P 115328-50-2P 115328-53-5P

115342-16-0P 115342-17-1P 115342-18-2P
115361-61-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antihypertensive)


RN 115328-37-5 HCAPLUS

CN 1-Piperazineethanol, α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 115328-38-6 HCAPLUS

CN 1-Piperazineethanol, 4-(4-fluorophenyl)- α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-39-7 HCAPLUS

CN 1-Piperazineethanol, α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 115328-40-0 HCAPLUS

CN 1-Piperazineethanol, 4-(2-methoxyphenyl)- α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-41-1 HCAPLUS

CN 1-Piperazineethanol, 4-(4-chlorophenyl)- α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-42-2 HCAPLUS

CN 1-Piperazineethanol, 4-(4-methoxyphenyl)- α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-43-3 HCAPLUS

CN 1-Piperazineethanol, α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 115328-44-4 HCAPLUS

CN 1-Piperazineethanol, 4-(2-chlorophenyl)- α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-45-5 HCAPLUS

CN 1-Piperazineethanol, α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]-4-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 115328-46-6 HCAPLUS

CN 1-Piperazineethanol, 4-(2-methylphenyl)- α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-47-7 HCAPLUS

CN 1-Piperazineethanol, 4-(3-methylphenyl)- α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-48-8 HCAPLUS

CN 1-Piperazineethanol, 4-(4-fluorophenyl)- α -[5-methyl-2-(2-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-49-9 HCAPLUS

CN 1-Piperazineethanol, 4-(4-fluorophenyl)- α -[5-methyl-2-(4-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 115328-50-2 HCAPLUS

CN 1-Piperazineethanol, 4-(4-fluorophenyl)- α -methyl- α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-53-5 HCAPLUS

CN 1-Piperazineethanol, 4-(4-fluorophenyl)-α-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]-, (R*,R*)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 115328-38-6

CMF C21 H24 F N5 O




CM 2

*CRN 133-37-9


CMF C4 H6 O6

Relative stereochemistry.




RN 115342-16-0 HCAPLUS

CN 1-Piperazineethanol, 4-(2-chloro-10,11-dihydrodibenz[b,f][1,4]oxazepin-11-yl)-α-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115342-17-1 HCAPLUS

CN 1-Piperazineethanol, 4-(3-chlorophenyl)-α-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 115342-18-2 HCAPLUS

CN 1-Piperazineethanol, 4-(4-fluorophenyl)-α-[5-methyl-2-(3-methyl-4-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115361-61-0 HCAPLUS

CN 1-Piperazineethanol, 4-(4-fluorophenyl)-α-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]-, (2R,3R)-2,3-dihydroxybutanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 115328-38-6

CMF C21 H24 F N5 O




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




IT 115328-54-6P 115328-55-7P 115328-56-8P
 115328-57-9P 115328-58-0P 115328-59-1P
 115328-60-4P 115328-61-5P 115328-62-6P
 115328-63-7P 115328-64-8P 115328-65-9P
 115328-66-0P 115328-67-1P 115342-19-3P
 115342-20-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as intermediate for antihypertensives)


RN 115328-54-6 HCAPLUS

CN Ethanone, 1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]-2-(4-phenyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 115328-55-7 HCAPLUS

CN Ethanone, 2-[4-(4-fluorophenyl)-1-piperazinyl]-1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-56-8 HCAPLUS

CN Ethanone, 1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]-2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 115328-57-9 HCAPLUS

CN Ethanone, 2-[4-(2-methoxyphenyl)-1-piperazinyl]-1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-58-0 HCAPLUS

CN Ethanone, 2-[4-(4-methoxyphenyl)-1-piperazinyl]-1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-59-1 HCAPLUS

CN Ethanone, 2-[4-(4-chlorophenyl)-1-piperazinyl]-1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 115328-60-4 HCAPLUS


CN Ethanone, 2-[4-(3-chlorophenyl)-1-piperazinyl]-1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 115328-61-5 HCAPLUS


CN Ethanone, 2-[4-(2-chloro-10,11-dihydrodibenz[b,f][1,4]oxazepin-11-yl)-1-piperazinyl]-1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)

INDEX NAME)




RN 115328-62-6 HCAPLUS

CN Ethanone, 2-[4-(2-chlorophenyl)-1-piperazinyl]-1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-63-7 HCAPLUS

CN Ethanone, 1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]-2-[4-(2-pyrimidinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 115328-64-8 HCAPLUS

CN Ethanone, 2-[4-(4-fluorophenyl)-1-piperazinyl]-1-[5-methyl-2-(3-methyl-4-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-65-9 HCAPLUS

CN Ethanone, 2-[4-(4-fluorophenyl)-1-piperazinyl]-1-[5-methyl-2-(2-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-66-0 HCAPLUS

CN Ethanone, 2-[4-(4-fluorophenyl)-1-piperazinyl]-1-[5-methyl-2-(4-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-67-1 HCAPLUS

CN Ethanone, 2-[4-(2-methylphenyl)-1-piperazinyl]-1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115342-19-3 HCAPLUS

CN Ethanone, 1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]-2-[4-(2-thiazolyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 115342-20-6 HCAPLUS

CN Ethanone, 2-[4-(3-methylphenyl)-1-piperazinyl]-1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



=> b uspatall

FILE 'USPATFULL' ENTERED AT 14:37:59 ON 18 SEP 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:37:59 ON 18 SEP 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr l21 2

L21 ANSWER 2 OF 12 USPATFULL on STN

AN 2004:159270 USPATFULL

TI Cannabinoid receptor ligands and uses thereof

IN Dow, Robert L., Groton, CT, UNITED STATES

Hammond, Marlys, Blue Bell, PA, UNITED STATES

PA Pfizer Inc. (U.S. corporation)

PI US2004122074 A1 20040624

AI 2003US-0702149 A1 20031104 (10)

PRAI 2002US-432911P 20021212 (60)

DT Utility

FS APPLICATION

LREP PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 3170

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment diseases, conditions and/or disorders modulated by cannabinoid receptor antagonists in animals are described herein. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 709033-15-8P 709033-17-0P 709033-18-1P
709033-19-2P 709033-20-5P 709033-21-6P
709033-22-7P 709033-23-8P 709033-25-0P
709033-27-2P 709033-29-4P 709033-30-7P
709033-31-8P 709033-32-9P 709033-33-0P
709033-34-1P 709033-35-2P 709033-41-0P
709033-42-1P

(claimed compound; preparation of pyrazoles and imidazoles as cannabinoid CB1 receptor antagonists)

IT 709033-46-5P 709033-47-6P 709033-48-7P
709033-50-1P 709033-52-3P 709033-54-5P
709033-56-7P 709033-58-9P 709033-60-3P
709033-62-5P 709033-63-6P 709033-66-9P
709033-70-5P 709033-74-9P 709033-76-1P
709033-78-3P 709033-80-7P 709033-82-9P
709033-84-1P 709033-86-3P 709033-88-5P
709033-89-6P 709033-90-9P 709033-91-0P
709033-92-1P 709033-93-2P 709033-94-3P
709033-95-4P 709033-96-5P 709033-97-6P

709033-98-7P 709033-99-8P 709034-00-4P
709034-01-5P 709034-02-6P 709034-03-7P
709034-04-8P 709034-05-9P 709034-06-0P
709034-07-1P 709034-08-2P 709034-09-3P
709034-10-6P 709034-11-7P 709034-12-8P
709034-13-9P 709034-14-0P 709034-15-1P
709034-16-2P 709034-17-3P 709034-18-4P
709034-19-5P 709034-20-8P 709034-21-9P
709034-22-0P 709034-23-1P 709034-24-2P
709034-25-3P 709034-26-4P 709034-27-5P
709034-28-6P 709034-29-7P 709034-30-0P
709034-31-1P 709034-32-2P 709034-33-3P
709034-34-4P 709034-35-5P 709034-36-6P
709034-37-7P 709034-38-8P 709034-39-9P
709034-40-2P 709034-41-3P 709034-42-4P
709034-44-6P 709034-45-7P 709034-46-8P
709034-47-9P 709034-48-0P 709034-49-1P
709034-50-4P 709034-51-5P 709034-52-6P
709034-53-7P 709034-54-8P 709034-55-9P
709034-56-0P 709034-57-1P 709034-58-2P
709034-59-3P 709034-60-6P 709034-61-7P
709034-62-8P 709034-63-9P 709034-64-0P
709034-65-1P 709034-66-2P 709034-67-3P
709034-68-4P 709034-69-5P 709034-70-8P
709034-71-9P 709034-72-0P 709034-73-1P
709034-74-2P 709034-75-3P 709034-76-4P
709034-77-5P 709034-78-6P 709034-79-7P
709034-80-0P 709034-81-1P 709034-82-2P
709034-83-3P 709034-84-4P 709034-85-5P
709034-86-6P 709034-87-7P 709034-88-8P
709034-89-9P 709034-90-2P 709034-91-3P
709034-92-4P 709034-93-5P 709034-94-6P
709034-95-7P 709034-96-8P 709034-97-9P
709034-98-0P 709034-99-1P 709035-00-7P
709035-01-8P 709035-02-9P 709035-03-0P
709035-04-1P 709035-05-2P 709035-06-3P
709035-07-4P 709035-08-5P 709035-09-6P
709035-10-9P 709035-11-0P 709035-12-1P
709035-13-2P 709035-14-3P 709035-15-4P
709035-16-5P 709035-17-6P 709035-18-7P
709035-19-8P 709035-20-1P 709035-21-2P
709035-22-3P 709035-23-4P 709035-24-5P
709035-25-6P 709035-26-7P 709035-27-8P
709035-28-9P 709035-29-0P 709035-30-3P
709035-31-4P 709035-32-5P 709035-33-6P
709035-34-7P 709035-35-8P 709035-36-9P
709035-37-0P 709035-38-1P 709035-39-2P
709035-40-5P 709035-41-6P 709035-42-7P
709035-43-8P 709035-44-9P 709035-45-0P
709035-46-1P 709035-47-2P 709035-48-3P
709035-49-4P 709035-50-7P 709035-51-8P
709035-52-9P 709035-53-0P 709035-54-1P
709035-55-2P 709035-56-3P 709035-57-4P
709035-58-5P 709035-59-6P 709035-60-9P
709035-61-0P 709035-62-1P 709035-63-2P
709035-64-3P 709035-65-4P 709035-66-5P
709035-67-6P 709035-68-7P 709035-69-8P
709035-70-1P 709035-71-2P 709035-72-3P
709035-73-4P 709035-74-5P 709035-75-6P
709035-76-7P 709035-77-8P 709035-78-9P
709035-79-0P 709035-80-3P 709035-81-4P
709035-82-5P 709035-83-6P 709035-84-7P
709035-85-8P 709035-86-9P 709035-87-0P
709035-88-1P 709035-89-2P 709035-90-5P
709035-92-7P 709035-94-9P 709035-95-0P
709035-96-1P 709035-97-2P 709035-98-3P

709035-99-4P 709036-00-0P 709036-01-1P

709036-02-2P 709036-03-3P

(preparation of pyrazoles and imidazoles as cannabinoid CB1 receptor antagonists)

IT 709036-04-4P 709036-05-5P 709036-06-6P

709036-07-7P 709036-08-8P 709036-10-2P

709036-12-4P 709036-15-7P 709036-18-0P

709036-21-5P 709036-24-8P 709036-26-0P

709036-28-2P 709036-31-7P 709036-33-9P

709036-35-1P 709036-37-3P 709036-38-4P

709036-39-5P 709036-40-8P 709036-41-9P

709036-42-0P 709036-43-1P 709036-44-2P

709036-45-3P 709036-46-4P 709036-47-5P

709036-48-6P 709036-49-7P 709036-50-0P

709036-51-1P 709036-52-2P 709036-53-3P

709036-54-4P 709036-68-0P 709036-69-1P

709036-70-4P 709036-71-5P

(preparation of pyrazoles and imidazoles as cannabinoid CB1 receptor antagonists)

IT 709036-72-6


(preparation of pyrazoles and imidazoles as cannabinoid CB1 receptor antagonists)

IT 709033-15-8P

(claimed compound; preparation of pyrazoles and imidazoles as cannabinoid CB1 receptor antagonists)

RN 709033-15-8 USPATFULL

CN Ethanone, 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-2-(1-piperidiny)- (9CI) (CA INDEX NAME)



=> d bib abs hitstr l21 1 3-12

L21 ANSWER 1 OF 12 USPATFULL on STN

AN 2005:50527 USPATFULL

TI Pharmaceutical composition for the prevention and treatment of addiction in a mammal

IN Coe, Jotham Wadsworth, Niantic, CT, UNITED STATES

Iredale, Philip A., Clinton, CT, UNITED STATES

McHardy, Stanton Furst, Coventry, RI, UNITED STATES

McLean, Stafford, Stonington, CT, UNITED STATES

PA Pfizer Inc (U.S. corporation)

PI US2005043327 A1 20050224

AI 2004US-0870209 A1 20040617 (10)

PRAI 2003US-496803P 20030821 (60)

DT Utility

FS APPLICATION

LREP PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2088

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical compositions are disclosed for the treatment of alcohol or cocaine dependence or addiction, tobacco dependence or addiction, reduction of alcohol withdrawal symptoms or aiding in the cessation or lessening of alcohol use or substance abuse or other behavioral dependencies including gambling. The pharmaceutical compositions are comprised of a therapeutically effective combination of an opioid receptor antagonist and a CB-1 receptor antagonist and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 709033-15-8 709033-17-0 709033-18-1
 709033-19-2 709033-20-5 709033-21-6
 709033-22-7 709033-23-8 709033-25-0
 709033-27-2 709033-29-4 709033-30-7
 709033-31-8 709033-32-9 709033-33-0
 709033-34-1 709033-35-2 709033-41-0
 709033-42-1

(opioid receptor antagonist-CB-1 receptor antagonist combination for prevention and treatment of addiction)


RN 709033-15-8 USPATFULL

CN Ethanone, 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 709033-17-0 USPATFULL

CN Ethanone, 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 709033-18-1 USPATFULL

CN Piperazine, 1-[2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-2-oxoethyl]-4-[(1-methyl-1H-pyrrol-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 709033-19-2 USPATFULL

CN Piperazine, 1-[2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-2-oxoethyl]-4-[(1-methylcyclopropyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 709033-20-5 USPATFULL

CN Acetamide, N-[1-[2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-2-oxoethyl]-4-piperidinyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 709033-21-6 USPATFULL

CN Ethanone, 1-[5-(4-chlorophenyl)-1-(2-fluorophenyl)-4-methyl-1H-pyrazol-3-yl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 709033-22-7 USPATFULL

CN Ethanone, 1-[5-(4-chlorophenyl)-1-(2-fluorophenyl)-4-methyl-1H-pyrazol-3-yl]-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 709033-23-8 USPATFULL

CN Piperazine, 1-[2-[5-(4-chlorophenyl)-1-(2-fluorophenyl)-4-methyl-1H-pyrazol-3-yl]-2-oxoethyl]-4-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 709033-25-0 USPATFULL

CN Ethanone, 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 709033-27-2 USPATFULL

CN Ethanone, 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-2-(tetrahydro-1,4-oxazepin-4(5H)-yl)- (9CI) (CA INDEX NAME)




RN 709033-29-4 USPATFULL

CN Ethanone, 1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-2-(1-oxa-8-azaspiro[4.5]dec-8-yl)- (9CI) (CA INDEX NAME)




RN 709033-30-7 USPATFULL

CN 1H-Pyrazole-3-methanol, 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl- α -[[1-(1-methylethyl)(phenylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 709033-31-8 USPATFULL

CN 1-Piperidineethanol, α -[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-3,5-dimethyl- (9CI) (CA INDEX NAME)


RN 709033-32-9 USPATFULL

CN 4-Piperidinecarboxamide, 1-[2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-2-hydroxyethyl]-4-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




RN 709033-33-0 USPATFULL

CN 1-Piperidineethanol, α -[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]-3,3-dimethyl- (9CI) (CA INDEX NAME)




RN 709033-34-1 USPATFULL

CN 1-Piperidineethanol, α -[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 709033-35-2 USPATFULL

CN 4-Morpholineethanol, α -[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 709033-41-0 USPATFULL

CN Ethanone, 1-[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-1H-imidazol-4-yl]-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 709033-42-1 USPATFULL

CN Ethanone, 1-[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-1H-imidazol-4-yl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



L21 ANSWER 3 OF 12 USPATFULL on STN

AN 96:39021 USPATFULL

TI Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives

IN Pascal, Jean C., Cachan, France

Lee, Chi-Ho, Palo Alto, CA, United States

Alps, Brian J., Linlithgow, Scotland

Pinhas, Henri, Paris, France

Whiting, Roger L., Los Altos, CA, United States

MacFarlane, Calum B., Linlithgow, Scotland

Beranger, Serge, Bretigny-Sur-Cedres, France

PA Syntex Pharmaceuticals, Ltd., Maidenhead, England (non-U.S. corporation)

PI US---5514800 19960507

AI 1993US-0124518 19930920 (8)

RLI Division of Ser. No. 1991US-0688193, filed on 19 Apr 1991, now patented, Pat. No. US---5276034 which is a division of Ser. No. 1988US-0260969, filed on 21 Oct 1988, now patented, Pat. No. US---5043447 which is a continuation-in-part of Ser. No. 1987US-0042181, filed on 24 Apr 1987, now patented, Pat. No. US---4829065

DT Utility

FS Granted

EXNAM Primary Examiner: Tsang, Cecilia

LREP Heller Ehrman White & McAuliffe

CLMN Number of Claims: 10

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2247

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted imidazolyl-alkyl-piperazine and diazepine derivatives of Formula A: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, m, n and q are defined as in the specification, and the pharmaceutically acceptable salts thereof. The compounds have calcium entry blocking activity with selectivity for cerebral blood vessels, and have protective activity against some of the deleterious effects resultant

upon cerebral ischemia.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 119514-74-8P 119514-82-8P

(preparation of, as pharmaceutical)


RN 119514-74-8 USPATFULL

CN Ethanone, 2-[4-(diphenylmethyl)-1-piperazinyl]-1-(5-methyl-2-phenyl-1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)



RN 119514-82-8 USPATFULL

CN 1-Piperazineethanol, 4-(diphenylmethyl)-α-(5-methyl-2-phenyl-1H-imidazol-4-yl)-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

L21 ANSWER 4 OF 12 USPATFULL on STN

AN 94:1427 USPATFULL

TI Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives

IN Pascal, Jean C., Cachan, France

Lee, Chi-Ho, Palo Alto, CA, United States

Alps, Brian J., Linlithgow, Scotland

Pinhas, Henri, Paris, France

Whiting, Roger L., Los Altos, CA, United States

MacFarlane, Calum B., Linlithgow, Scotland

Beranger, Serge, Bretigny-sur-Cedres, France


PA Dow, Robert J., Edinburgh, Scotland
 PI Syntex Pharmaceutical Ltd., Maidenhead, England (non-U.S. corporation)
 PI US---5276034 19940104
 AI 1991US-0688193 19910419 (7)
 RLI Division of Ser. No. 1988US-0260969, filed on 21 Oct 1988, now patented,
 Pat. No. US---5043447 which is a continuation-in-part of Ser. No.
 1987US-0042181, filed on 24 Apr 1987, now patented, Pat. No.
 US---4829065
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Tsang, Cecilia
 LREP Lowin, David A., Moran, Tom M., Desjardins, Cathleen M.
 CLMN Number of Claims: 16
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 2218

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Substituted imidazolyl-alkyl-piperazine and diazepine derivatives and the pharmaceutically acceptable salts thereof are useful for treating mammals having any of a variety of disease states. These disease states include: 1) diseases treated by direct neuronal protection, including focal and global ischemia, spinal injuries, and head trauma, and neurological diseases including Alzheimer's and Huntington's chorea; 2) uraemic and hyponatraemic encephalopathy; 3) diseases treated by diuresis; 4) diseases treated by calcium channel antagonism, including cardiovascular diseases (i.e. hypertension, angina, stable and unstable angina, Prinzmetal angina, arrhythmia, thrombosis, embolism, and congestive heart failure including chronic or acute cardiac failure), diseases characterized by ischemia of lower legs due to peripheral vascular disease (e.g., intermittent claudication), diseases characterized by spasms of smooth muscle (i.e., spasms of the ureter, spasms of the bladder, uterine cramps, and irritable bowel syndrome), and prevention of vasoconstriction and/or ischemic tissue damage during a surgical procedure (i.e., bypass grafts, angiography, angioplasty, organ preservation during transplant, hypertensive crisis or post operative hypertension).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 119514-74-8P 119514-82-8P
 (preparation of, as pharmaceutical)
 RN 119514-74-8 USPATFULL
 CN Ethanone, 2-[4-(diphenylmethyl)-1-piperazinyl]-1-(5-methyl-2-phenyl-1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)



RN 119514-82-8 USPATFULL
 CN 1-Piperazineethanol, 4-(diphenylmethyl)-α-(5-methyl-2-phenyl-1H-imidazol-4-yl)-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

L21 ANSWER 5 OF 12 USPATFULL on STN
 AN 93:85286 USPATFULL
 TI Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives
 IN Pascal, Jean C., Cachan, France
 Lee, Chi-Ho, Palo Alto, CA, United States
 Alps, Brian J., Linlithgow, Scotland
 Pinhas, Henri, Paris, France
 Whiting, Roger L., Los Altos, CA, United States
 PA Syntex Pharmaceuticals, Ltd., Maidenhead, England (non-U.S. corporation)
 PI US---5252736 19931012
 AI 1991US-0789230 19911107 (7)
 DCD 20090225
 RLI Continuation of Ser. No. 1991US-0652141, filed on 7 Feb 1991, now patented, Pat. No. US---5091428 which is a division of Ser. No. 1990US-0505379, filed on 6 Apr 1990, now patented, Pat. No. US---5010075 which is a division of Ser. No. 1989US-0313656, filed on 21 Feb 1989, now patented, Pat. No. US---4935417 which is a division of Ser. No. 1987US-0042181, filed on 24 Apr 1987, now patented, Pat. No. US---4829065
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Tsang, Cecilia
 LREP Desjardins, Cathleen, Lowin, David A., Moran, Tom M.
 CLMN Number of Claims: 7
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1436
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Substituted imidazolyl-alkyl-piperazine and diazepine derivatives of Formula A: ##STR1## wherein: R.sup.1 is aryl, lower alkyl, cycloalkyl or hydrogen;

R.sup.2 is aryl, lower alkyl or hydrogen;

R.sup.3 is lower alkyl, hydroxy, or hydrogen;

R.sup.4 is aryl or hydrogen;

R.sup.5 is aryl or hydrogen;

m is two or three;

n is zero, one or two, provided that when R^{sup.3} is hydroxy, n is one or two; and

q is zero, one, two, or three;

and the pharmaceutically acceptable salts thereof, are calcium channel antagonists useful for treating mammals having a variety of disease states, such as stroke, epilepsy, hypertension, angina, migraine, arrhythmia, thrombosis, embolism and also for treatment of spinal injuries.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 119514-74-8P 119514-82-8P

(preparation of, as pharmaceutical)


RN 119514-74-8 USPATFULL

CN Ethanone, 2-[4-(diphenylmethyl)-1-piperazinyl]-1-(5-methyl-2-phenyl-1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)



RN 119514-82-8 USPATFULL


CN 1-Piperazineethanol, 4-(diphenylmethyl)-α-(5-methyl-2-phenyl-1H-imidazol-4-yl)-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

L21 ANSWER 6 OF 12 USPATFULL on STN
AN 92:70440 USPATFULL
TI Cationic effect-driven carbinol/amine reaction
IN Beranger, Serge, Bretigny-Sur-Orge, France
Francois, Bruno, Sainte Genevieve Des Bois, France
PA Laboratoires Syntex, Puteaux, France (non-U.S. corporation)
PI US---5142052 19920825
AI 1988US-0260965 19881021 (7)
PRAI 1988EP-0303646 19880422
DT Utility
FS Granted
EXNAM Primary Examiner: Bond, Robert T.; Assistant Examiner: Ward, E. C.
LREP Lowin, David A., Moran, Tom M.
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 713
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Aryl- and heterocyclic-methanamines are prepared by reacting a hydroxy-aryl carbinol or a heterocyclic carbinol with a primary or a secondary amine in the presence of a cationic effect reagent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 119514-74-8P 119514-82-8P
(preparation of, as pharmaceutical)
RN 119514-74-8 USPATFULL
CN Ethanone, 2-[4-(diphenylmethyl)-1-piperazinyl]-1-(5-methyl-2-phenyl-1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)



RN 119514-82-8 USPATFULL
CN 1-Piperazineethanol, 4-(diphenylmethyl)- α -(5-methyl-2-phenyl-1H-imidazol-4-yl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

L21 ANSWER 7 OF 12 USPATFULL on STN

AN 92:15054 USPATFULL

TI Substituted imidazoly-alkyl-piperazine and -diazepine derivatives

IN Pascal, Jean C., Cachan, France

Lee, Chi-Ho, Palo Alto, CA, United States

Alps, Brian J., Linlithgow, Scotland

Pinhas, Henri, Paris, France

Whiting, Roger L., Los Altos, CA, United States

PA Syntex Pharmaceuticals, Ltd., Hamilton, Bermuda (non-U.S. corporation)

PI US---5091428 19920225

AI 1991US-0652141 19910207. (7)

RLI Division of Ser. No. 1990US-0505379, filed on 6 Apr 1990, now patented,
Pat. No. US---5010075 which is a division of Ser. No. 1989US-0313656,
filed on 21 Feb 1989, now patented, Pat. No. US---4938417 which is a
division of Ser. No. 1987US-0042181, filed on 24 Apr 1987, now patented,
Pat. No. US---4829065

DT Utility

FS Granted

EXNAM Primary Examiner: Shen, Cecilia

LREP Lowin, David A., Moran, Tom M.

CLMN Number of Claims: 31

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1486

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted imidazoly-alkyl-piperazine and diazepine derivatives of
Formula A: ##STR1## wherein: R.sup.1 is aryl, lower alkyl, cycloalkyl or
hydrogen;

R.sup.2 is aryl, lower alkyl or hydrogen;

R.sup.3 is lower alkyl, hydroxy, or hydrogen;

R.sup.4 is aryl or hydrogen;

R.sup.5 is aryl or hydrogen;

m is two or three;

n is zero, one or two, provided that when R.sup.3 is hydroxy, n is one
or two; and

q is zero, one, two, or three;

and the pharmaceutically acceptable salts thereof, are calcium channel antagonists useful for treating mammals having a variety of disease states, such as stroke, epilepsy, hypertension, angina, migraine, arrhythmia, thrombosis, embolism and also for treatment of spinal injuries.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 119514-74-8P 119514-82-8P

(preparation of, as pharmaceutical)


RN 119514-74-8 USPATFULL

CN Ethanone, 2-[4-(diphenylmethyl)-1-piperazinyl]-1-(5-methyl-2-phenyl-1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)



RN 119514-82-8 USPATFULL

CN 1-Piperazineethanol, 4-(diphenylmethyl)-α-(5-methyl-2-phenyl-1H-imidazol-4-yl)-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

L21 ANSWER 8 OF 12 USPATFULL on STN

AN 91:68999 USPATFULL

TI Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives

IN Pascal, Jean C., Cachan, France

Lee, Chi-Ho, Palo Alto, CA, United States
 Alps, Brian J., Linlithgow, Scotland
 Pinhas, Henri, Paris, France
 Whiting, Roger L., Los Altos, CA, United States
 Macfarlane, Calum B., Linlithgow, Scotland
 Beranger, Serge, Bretigny-Sur-Cedres, France
 Dow, Robert J., Edinburgh, Scotland
 PA Syntex Pharmaceuticals, Ltd., Berkshire, England (non-U.S. corporation)
 PI US---5043447 19910827
 AI 1988US-0260969 19881021 (7)
 RLI Continuation-in-part of Ser. No. 1987US-0042181, filed on 24 Apr 1987,
 now patented, Pat. No. US---4829065
 PRAI 1988EP-0303646 19880422
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Shen, Cecilia
 LREP Lowin, David A., Moran, Tom M.
 CLMN Number of Claims: 11
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 2177

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted imidazolyl-alkyl-piperazine and diazepine derivatives of
 Formula A: ##STR1## wherein: R.sup.1 is aryl, lower alkyl, cycloalkyl or
 hydrogen;

R.sup.2 is aryl, lower alkyl or hydrogen;

R.sup.3 is lower alkyl, hydroxy, or hydrogen;

R.sup.4 is aryl or hydrogen;

R.sup.5 is aryl or hydrogen;

m is two or three;

n is zero, one or two,

provided that when R.sup.3 is hydroxy, n is one or two; and

q is zero, one, two, or three;

and the pharmaceutically acceptable salts thereof, are useful for
 treating mammals having any of a variety of disease states including:

diseases treated by direct neuronal protection, such as ischemia
 including focal and global ischemia, spinal injuries, head trauma, and
 neurological diseases such as Alzheimer's and Huntington's chorea;

diseases treated by inhibition of sodium ion, such as uremic and
 hyponatremic encephalopathy; and

diseases treated with calcium channel antagonists, including:

diseases treated by inhibiting cerebrovascular vasospasm and by
 cerebrovascular vasodilation, such as migraine, stroke, vasospasm due to
 subarachnoid hemorrhage, epilepsy or epileptic psychotic symptoms, and
 cerebrovascular ischemia induced by cocaine abuse; and

cardiovascular diseases, such as hypertension, angina, stable and
 unstable angina, Prinzmetal angina, arrhythmia, thrombosis, embolism,
 and congestive heart failure such as chronic or acute cardiac failure;
 and

ischemia of lower legs due to peripheral vascular disease, e.g.,
 intermittent claudication;

spasms of smooth muscle: such as the ureter, the bladder, uterine cramps, diuresis, and irritable bowel syndrome; and

uses during surgery: such as bypass grafts, angiography, angioplasty, organ preservation during transplant, hypertensive crisis, or post operative hypertension.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 119514-74-8P 119514-82-8P

(preparation of, as pharmaceutical)


RN 119514-74-8 USPATFULL

CN Ethanone, 2-[4-(diphenylmethyl)-1-piperazinyl]-1-(5-methyl-2-phenyl-1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)



RN 119514-82-8 USPATFULL

CN 1-Piperazineethanol, 4-(diphenylmethyl)-α-(5-methyl-2-phenyl-1H-imidazol-4-yl)-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

L21 ANSWER 9 OF 12 USPATFULL on STN

AN 91:32446 USPATFULL

TI Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives

IN Pascal, Jean C., Cachan, France

Lee, Chi-Ho, Palo Alto, CA, United States
Alps, Brian J., Linlithgow, Scotland
Pinhas, Henri, Paris, France
Whiting, Roger L., Los Altos, CA, United States
PA Syntex Pharmaceuticals Ltd., Berkshire, England (non-U.S. corporation)
PI US---5010075 19910423
AI 1990US-0505379 19900406 (7)
RLI Division of Ser. No. 1989US-0313656, filed on 21 Feb 1989, now patented,
Pat. No. US---4935417 which is a division of Ser. No. 1987US-0042181,
filed on 24 Apr 1987, now patented, Pat. No. US---4829065
DT Utility
FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Dalton, Philip I.
LREP Lowin, David A., Moran, Tom M.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1,10
DRWN No Drawings
LN.CNT 1450
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Substituted imidazolyl-alkyl-piperazine and diazepine derivatives of
Formula A: ##STR1## wherein: R.sup.1 is aryl, lower alkyl, cycloalkyl or
hydrogen;

R.sup.2 is aryl, lower alkyl or hydrogen;

R.sup.3 is lower alkyl, hydroxy, or hydrogen;

R.sup.4 is aryl or hydrogen;

R.sup.5 is aryl or hydrogen;


m is two or three;

n is zero, one or two, provided that when R.sup.3 is hydroxy, n is one
or two; and

q is zero, one, two, or three;


and the pharmaceutically acceptable salts thereof, are calcium channel
antagonists useful for treating mammals having a variety of disease
states, such as stroke, epilepsy, hypertension, angina, migraine,
arrhythmia, thrombosis, embolism and also for treatment of spinal
injuries.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 119514-74-8P 119514-82-8P
(preparation of, as pharmaceutical)
RN 119514-74-8 USPATFULL
CN Ethanone, 2-[4-(diphenylmethyl)-1-piperazinyl]-1-(5-methyl-2-phenyl-1H-
imidazol-4-yl)- (9CI) (CA INDEX NAME)



RN 119514-82-8 USPATFULL

CN 1-Piperazineethanol, 4-(diphenylmethyl)-α-(5-methyl-2-phenyl-1H-imidazol-4-yl)-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

L21 ANSWER 10 OF 12 · USPATFULL on STN

AN 90:48802 USPATFULL

TI Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives for treating cerebrovascular disease

IN Pascal, Jean C., Cachan, France

Lee, Chi-Ho, Palo Alto, CA, United States

Alps, Brian J., Linlithgow, Scotland

Pinhas, Henri, Paris, France

Whiting, Roger L., Los Altos, CA, United States

PA Syntex Pharmaceuticals Ltd., Hamilton, Bermuda (non-U.S. corporation)

PI US---4935417 19900619

AI 1989US-0313656 19890221 (7)

RLI Division of Ser. No. 1987US-0042181, filed on 24 Apr 1987, now patented, Pat. No. US---4829065

DT Utility

FS Granted

EXNAM Primary Examiner: Friedman, Stanley J.

LREP Lowin, David A., Moran, Tom M.

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1480

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted imidazolyl-alkyl-piperazine and diazepine derivatives of
Formula A: ##STR1## wherein: R.sup.1 is aryl, lower alkyl, cycloalkyl or
hydrogen;

R.sup.2 is aryl, lower alkyl or hydrogen;

R.sup.3 lower alkyl, hydroxy, or hydrogen;

R.sup.4 aryl or hydrogen;

R.sup.5 aryl or hydrogen;

m is two or three;

n is zero, one or two,

provided that when R.sup.3 hydroxy, n is one or two; and

q is zero, one, two, or three;

and the pharmaceutically acceptable salts thereof, are calcium channel
antagonists useful for treating mammals having a variety of disease
states, such as stroke, epilepsy, hypertension, angina, migraine,
arrhythmia, thrombosis, embolism and also for treatment of spinal
injuries.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 119514-74-8P 119514-82-8P

(preparation of, as pharmaceutical)


RN 119514-74-8 USPATFULL

CN Ethanone, 2-[4-(diphenylmethyl)-1-piperazinyl]-1-(5-methyl-2-phenyl-1H-
imidazol-4-yl)- (9CI) (CA INDEX NAME)



RN 119514-82-8 USPATFULL

CN 1-Piperazineethanol, 4-(diphenylmethyl)-α-(5-methyl-2-phenyl-1H-
imidazol-4-yl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

L21 ANSWER 11 OF 12 USPATFULL on STN

AN 89:36735 USPATFULL

TI Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives

IN Pascal, Jean C., Cachan, France

Lee, Chi-Ho, Palo Alto, CA, United States

Alps, Brian J., Linlithgow, Scotland

Pinhas, Henri, Paris, France

Whiting, Roger L., Los Altos, CA, United States

PA Syntex Pharmaceuticals, Ltd., Maidenhead, England (non-U.S. corporation)

PI US---4829065 19890509

AI 1987US-0042181 19870424 (7)

DT Utility

FS Granted

EXNAM Primary Examiner: Friedman, Stanley J.

LREP Lowin, David A., Moran, Tom M.

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1470

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted imidazolyl-alkyl-piperazine and diazepine derivatives of
Formula A: ##STR1## wherein: R.sup.1 is aryl, lower alkyl, cycloalkyl or
hydrogen;

R.sup.2 is aryl, lower alkyl or hydrogen;

R.sup.3 is lower alkyl, hydroxy, or hydrogen;

R.sup.4 is aryl or hydrogen;

R.sup.5 is aryl or hydrogen;

m is two or three;

n is zero, one or two,

provided that when R.sup.3 is hydroxy, n is one or two; and

q is zero, one, two, or three;

and the pharmaceutically acceptable salts thereof, are calcium channel
antagonists useful for treating mammals having a variety of disease

states, such as stroke, epilepsy, hypertension, angina, migraine, arrhythmia, thrombosis, embolism and also for treatment of spinal injuries.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 119514-74-8P 119514-82-8P

(preparation of, as pharmaceutical)


RN 119514-74-8 USPATFULL

CN Ethanone, 2-[4-(diphenylmethyl)-1-piperazinyl]-1-(5-methyl-2-phenyl-1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)



RN 119514-82-8 USPATFULL

CN 1-Piperazineethanol, 4-(diphenylmethyl)-α-(5-methyl-2-phenyl-1H-imidazol-4-yl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

L21 ANSWER 12 OF 12 USPATFULL on STN

AN 88:17835 USPATFULL

TI α-[5-methyl-2-(pyridinyl)-1H-imidazol-4-yl]substituted-1-piperazineethanols useful for treating hypertension

IN Hofmann, Corris M., Hohokus, NJ, United States

Newman, Howard, Monsey, NY, United States


Tomcufcik, Andrew S., Old Tappan, NJ, United States

PA American Cyanamid Company, Stamford, CT, United States (U.S.)


corporation)
 PI US---4732895 19880322
 AI 1986US-0858633 19860502 (6)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Daus, Donald G.; Assistant Examiner: Shen, Cecilia
 LREP Conroy, Jr., Edward A.
 CLMN Number of Claims: 23
 ECL Exemplary Claim: 1,21,23
 DRWN No Drawings
 LN.CNT 539
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB This disclosure describes novel substituted α -[5-methyl-2-pyridyl-1H-imidazol-4-yl]-1-piperazineethanols which possess hypotensive activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 115328-37-5P 115328-38-6P 115328-39-7P
 115328-40-0P 115328-41-1P 115328-42-2P
 115328-43-3P 115328-44-4P 115328-45-5P
 115328-46-6P 115328-47-7P 115328-48-8P
 115328-49-9P 115328-50-2P 115328-53-5P
 115342-16-0P 115342-17-1P 115342-18-2P
 115361-61-0P
 (preparation of, as antihypertensive)
 RN 115328-37-5 USPATFULL
 CN 1-Piperazineethanol, α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 115328-38-6 USPATFULL
 CN 1-Piperazineethanol, 4-(4-fluorophenyl)- α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-39-7 USPATFULL
 CN 1-Piperazineethanol, α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 115328-40-0 USPATFULL

CN 1-Piperazineethanol, 4-(2-methoxyphenyl)- α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-41-1 USPATFULL

CN 1-Piperazineethanol, 4-(4-chlorophenyl)- α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-42-2 USPATFULL

CN 1-Piperazineethanol, 4-(4-methoxyphenyl)- α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-43-3 USPATFULL

CN 1-Piperazineethanol, α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 115328-44-4 USPATFULL

CN 1-Piperazineethanol, 4-(2-chlorophenyl)- α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-45-5 USPATFULL

CN 1-Piperazineethanol, α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]-4-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 115328-46-6 USPATFULL

CN 1-Piperazineethanol, 4-(2-methylphenyl)- α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-47-7 USPATFULL

CN 1-Piperazineethanol, 4-(3-methylphenyl)- α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-48-8 USPATFULL

CN 1-Piperazineethanol, 4-(4-fluorophenyl)- α -[5-methyl-2-(2-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-49-9 USPATFULL

CN 1-Piperazineethanol, 4-(4-fluorophenyl)- α -[5-methyl-2-(4-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 115328-50-2 USPATFULL

CN 1-Piperazineethanol, 4-(4-fluorophenyl)- α -methyl- α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]-, (9CI) (CA INDEX NAME)




RN 115328-53-5 USPATFULL

CN 1-Piperazineethanol, 4-(4-fluorophenyl)- α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]-, (R*,R*)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 115328-38-6

CMF C21 H24 F N5 O




CM 2

CRN 133-37-9

CMF C4 H6 O6


Relative stereochemistry.



RN 115342-16-0 USPATFULL


CN 1-Piperazineethanol, 4-(2-chloro-10,11-dihydrodibenz[b,f][1,4]oxazepin-11-yl)- α -[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA

INDEX NAME)




RN 115342-17-1 USPATFULL

CN 1-Piperazineethanol, 4-(3-chlorophenyl)-α-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 115342-18-2 USPATFULL

CN 1-Piperazineethanol, 4-(4-fluorophenyl)-α-[5-methyl-2-(3-methyl-4-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115361-61-0 USPATFULL

CN 1-Piperazineethanol, 4-(4-fluorophenyl)-α-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]-, (2R,3R)-2,3-dihydroxybutanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 115328-38-6


CMF C21 H24 F N5 O



CM 2

CRN 87-69-4
 CMF C4 H6 O6
 CDES 1:R2:R*,R*

Absolute stereochemistry.




IT 115328-54-6P 115328-55-7P 115328-56-8P
 115328-57-9P 115328-58-0P 115328-59-1P
 115328-60-4P 115328-61-5P 115328-62-6P
 115328-63-7P 115328-64-8P 115328-65-9P
 115328-66-0P 115328-67-1P 115342-19-3P
 115342-20-6P

(preparation of, as intermediate for antihypertensives)


RN 115328-54-6 USPATFULL

CN Ethanone, 1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]-2-(4-phenyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 115328-55-7 USPATFULL

CN Ethanone, 2-[4-(4-fluorophenyl)-1-piperazinyl]-1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-56-8 USPATFULL

CN Ethanone, 1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]-2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 115328-57-9 USPATFULL

CN Ethanone, 2-[4-(2-methoxyphenyl)-1-piperazinyl]-1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-58-0 USPATFULL

CN Ethanone, 2-[4-(4-methoxyphenyl)-1-piperazinyl]-1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-59-1 USPATFULL

CN Ethanone, 2-[4-(4-chlorophenyl)-1-piperazinyl]-1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 115328-60-4 USPATFULL


CN Ethanone, 2-[4-(3-chlorophenyl)-1-piperazinyl]-1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 115328-61-5 USPATFULL


CN Ethanone, 2-[4-(2-chloro-10,11-dihydrodibenz[b,f][1,4]oxazepin-11-yl)-1-piperazinyl]-1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)

INDEX NAME)




RN 115328-62-6 USPATFULL

CN Ethanone, 2-[4-(2-chlorophenyl)-1-piperazinyl]-1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-63-7 USPATFULL

CN Ethanone, 1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]-2-[4-(2-pyrimidinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 115328-64-8 USPATFULL

CN Ethanone, 2-[4-(4-fluorophenyl)-1-piperazinyl]-1-[5-methyl-2-(3-methyl-4-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-65-9 USPATFULL

CN Ethanone, 2-[4-(4-fluorophenyl)-1-piperazinyl]-1-[5-methyl-2-(2-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-66-0 USPATFULL

CN Ethanone, 2-[4-(4-fluorophenyl)-1-piperazinyl]-1-[5-methyl-2-(4-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115328-67-1 USPATFULL

CN Ethanone, 2-[4-(2-methylphenyl)-1-piperazinyl]-1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 115342-19-3 USPATFULL

CN Ethanone, 1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]-2-[4-(2-thiazolyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 115342-20-6 USPATFULL

CN Ethanone, 2-[4-(3-methylphenyl)-1-piperazinyl]-1-[5-methyl-2-(3-pyridinyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 13:54:06 ON 18 SEP 2006)

FILE 'HCAPLUS' ENTERED AT 13:54:13 ON 18 SEP 2006

L1 1 (US2003-702149 OR US2002-432911#)/AP, PRN OR US2004122074
E DOW R/AU
L2 80 E3, E8, E22, E25-27
E DOW B/AU
L3 5 E3, E6
E HAMMOND M/AU
L4 135 E3-17
E HAMMOND MARLYS/AU
L5 39 E3
L6 12609 PFIZER/CS, PA

FILE 'REGISTRY' ENTERED AT 13:57:30 ON 18 SEP 2006

FILE 'HCAPLUS' ENTERED AT 13:57:30 ON 18 SEP 2006

L7 TRA L1 1- RN : 324 TERMS

FILE 'REGISTRY' ENTERED AT 13:57:30 ON 18 SEP 2006

L8 324 SEA L7
L9 315 L8 AND (NCNC2 OR N2C3)/ES
L10 STR
L11 1 L10
L12 1309520 (NCNC2 OR N2C3)/ES
L13 0 L10 SAM SUB=L12
L14 SCR 1994 AND 1839
L15 0 L10 AND L14 SAM SUB=L12
L16 347 L10 AND L14 FULL SUB=L12
L17 291 L16 AND L8
SAV TEM L16 SAC149F0/A

FILE 'HCAPLUS' ENTERED AT 14:34:10 ON 18 SEP 2006

L18 4 L16
L19 2 L18 AND L1-6
L20 2 L18 NOT L19

FILE 'USPATFULL, USPAT2' ENTERED AT 14:34:39 ON 18 SEP 2006

L21 12 L16

FILE 'HCAOLD' ENTERED AT 14:35:34 ON 18 SEP 2006

L22 0 L16

=>